Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-na ïve Prostate Cancer: A Systematic Review and Network Meta-analysis

Conclusions We did not identify a significant difference in OS between Abi-ADT and Doce-ADT for men with hormone-naïve high-risk or metastatic PCa, although Bayesian analysis demonstrates a high likelihood that Abi-ADT was preferred. Patient summary We synthesized the evidence available from studies examining the administration of docetaxel or abiraterone in combination with hormonal therapy for patients with newly diagnosed, advanced prostate cancer. While these studies did not directly compare these agents, we used methodological techniques to indirectly compare them and found no significant difference in overall survival. A number of recent randomized controlled trials have demonstrated the benefit of adding abiraterone and prednisone or docetaxel to androgen deprivation therapy in men with hormone-naïve metastatic prostate cancer. However, which treatment to choose remains unclear. In this network meta-analysis, we found no significant difference in survival between men treated with abiraterone and prednisone and those treated with docetaxel in addition to androgen deprivation therapy.
Source: European Urology - Category: Urology & Nephrology Source Type: research